LUMINATI
23.7.2019 10:02:11 CEST | Business Wire | Press release
Luminati , the Israeli company that allows businesses to experience the web through the eyes of individual consumers throughout the world, today announced it has received a Market Leadership Award in the first independent analysis of the sector. Luminati’s enterprise IP proxy network (IPPN) services for global retailers, brand owners and advertising networks feature strongly in the report by analyst firm Frost & Sullivan. The report outlines a relatively new, but rapidly growing market and recognizes Luminati’s leading position in the provision of solutions that are increasingly important for businesses to remain competitive and compliant in the digital landscape. [S1]
“The market for enterprise IP proxy network solutions is in its early growth stages, basically being invented by Luminati only a few years ago. With the more specialized targeting of customers by demographics and location, companies are finding it more difficult than ever to do competitive analysis and verify advertising, security, and website performance. Companies not familiar with these website practices or Internet Protocol proxy network (IPPN) solutions are at risk of gathering incorrect data and left behind technology-wise,” noted Robert Cavin, Industry Analyst, Digital Media, Frost & Sullivan.
All online businesses today rely on the market data they harvest from the Web - retailers need pricing and offers comparisons, global brands need to check and manage how their products are presented and ad networks need to verify compliance. Unfortunately, with an increasingly personalized and geo-targeted Web, searching for that data from one, or even multiple locations is unlikely to deliver any meaningful business intelligence. A once transparent and open Web has become increasingly opaque.
Luminati gives back that transparency by shedding light on what’s really going on beneath the surface of the web. Luminati’s Enterprise IP Proxy Network (IPPN) harnesses the IP addresses of over 35 million opted-in end-users worldwide to provide businesses with a real and accurate view of the web, exactly how actual consumers see it, at every geographic location. By seeing the web from any perspective, without being blocked or misled, businesses can protect their brand, research competitors, monitor for security issues, test ads and ultimately maintain a competitive edge.
“The Frost & Sullivan report is encouraging reading, not only for Luminati, but as a means to alert the market to the potential for access to unique data and intelligence ,” said Or Lenchner, Luminati CEO . “Ours is a relatively new industry, but one that is bringing back transparency to the Web. Ironically, the technologies that are now universally deployed to personalize the user experience are also used to severely limit legitimate research .”
“That research helps companies around the world to compete on a level playing field, verify brand presentation, gather public data, test application performance, and limit fraud. That can only be a good thing in a global market but it’s critical that companies work with a responsible provider of IPPN services to protect their own reputation ,” continued Lenchner.
Frost & Sullivan’s report names Luminati the 2019 global market leader in the Enterprise IP Proxy Network market, and acknowledges how the company has revolutionized the technology through its residential peer-to-peer network. What’s more, the analysis identifies Luminati’s technical leadership and strict adherence to compliance procedures as factors that will likely cement the company’s leadership position over the coming years.
Key findings from the Frost & Sullivan report include:
- Despite the need amongst enterprises for competitor analysis, price comparison and data gathering, a significant proportion of the market is not aware of IPPN services – they risk losing revenue and customers to those businesses taking advantage of the benefits the technology delivers
- Luminati’s services currently account for more than half of global revenues; the company is positioned as the market leader based on penetration, product line and competitive strategy
-
The top five use cases for enterprise IPPN by revenue (2018) are:
- Price comparison
- Ad verification
- Fraud protection
- Data collection
- Brand protection
- Revenues are expected to reach nearly USD $260M by 2025
-ENDS-
About Luminati
Founded in 2014, Luminati is the world’s largest proxy service, aimed at bringing complete transparency back to the internet. The company’s first-of-its-kind enterprise IP proxy network (IPPN) enables businesses to level the global competitive landscape by collecting online data that may otherwise mislead them, or they may be blocked from accessing.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works collaboratively with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190723005394/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
